相关实验视频
Updated: Jul 15, 2025

05:07
Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
Published on: June 23, 2019
6.7K
基于伊米达索皮里丁的提亚衍生物作为潜在的抗糖尿病剂:合成,体外生物活性和分子建模方法
Rafaqat Hussain1, Wajid Rehman1, Shoaib Khan1
1Department of Chemistry, Hazara University, Mansehra 21120, Pakistan.
Pharmaceuticals (Basel, Switzerland)
|September 28, 2023
概括
合成了新的提亚衍生物,并测试了它们抑制α-葡萄糖酶的能力. 化合物4a和4o显示出最强的α-葡萄糖酶抑制,表明糖尿病管理的潜力.
科学领域:
- 药用化学 医学化学
- 酶学 是一种酶学.
- 药物发现 药物发现 药物发现
背景情况:
- 阿尔法-葡萄糖酶是碳水化合物代谢中的一个关键酶.
- 抑制α-葡萄糖酶可以帮助管理2型糖尿病.
- 目前正在积极寻找针对alpha-glucosidase的新型治疗剂.
研究的目的:
- 合成和评估新型的含有伊米达索皮里丁部分的提亚衍生物.
- 评估这些化合物的体外α-葡萄糖酶抑制潜力.
- 为了研究强效抑制剂与α-葡萄糖酶活性部位的结合相互作用.
主要方法:
- 提亚衍生物 (4a-p化合物) 的合成.
- 在体外酶抑制试验中,使用阿卡尔作为参考.
- 分子对接分析以探索结合模式.
- 使用光谱方法进行结构阐明 (1H-NMR,13C-NMR,HREI-MS).
主要成果:
- 化合物4a,4g,4o和4p表现出显著的α-葡萄糖酶抑制活性.
- 化合物4a (IC50 = 5.57 ± 3.45) 和4o (IC50 = 7.16 ± 1.40) 显示出更高的功效.
- 对接分析显示了酶活性部位内的4a和4o支架的强有力的结合相互作用.
结论:
- 合成的醇衍生物,特别是4a和4o,是α-葡萄糖酶的强有力的抑制剂.
- 这些化合物显示出作为新抗糖尿病药物开发的领先候选人的希望.
- 需要进一步的研究来探索它们的治疗潜力 in vivo.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
223
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
223
Antihypertensive Drugs: Thiazide-Class Diuretics
727
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
727
Oral Hypoglycemic Agents: Sulfonylureas
226
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
226
Oral Hypoglycemic Agents: Glinides
176
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
176
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
196
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
196
Dipeptidyl Peptidase 4 Inhibitors
204
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
204

